LA JOLLA, Calif., October 10, 2022–(BUSINESS WIRE)–DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced its presentation at the Biomarkers & Precision Medicine USA Congress, held from Oct. 3-4 in San Diego. The 6th annual event featured industry-leading speakers from the pharma, biotech and academic spaces, sharing new case studies, innovative data and industry outlooks.
Erica Montano, Ph.D., a DermTech Stratum™ research scientist, presented on the translational medicine services of DermTech Stratum and its precision-based approach to dermatology. The presentation, titled “Translational Research to Revolutionize Dermatologic Care,” emphasized the Company’s proprietary Smart Sticker™ and platform technology, highlighting its capabilities, specializations and advantages.
By non-invasively capturing genomic and proteomic material in the epidermis, DermTech’s Smart Sticker and platform technology leverage skin gene and protein expression profiles in a clinical research setting to deliver accurate, objective and useful information; identify biomarkers that may be useful in stratifying a disease of interest or disease subgroup; and determine patient response to a selected target therapeutic. Additionally, the integration and implementation of the Smart Sticker in clinical trials improves patient enrollment in research studies and thus, data collection, as it is…
